By ending the agreement, Quanterix regains full control over its Simoa immunoassay technology and its potential use for in vitro diagnostic purposes.
The test will be based on MRM Proteomics' immunoMALDI approach, which uses antibody enrichment of target proteins followed by analysis via MALDI mass spec.
Lunaphore's LabSat Frozen technology aims to automate biomarker-specific frozen section staining and enable performing IHC assays within minutes.
The biomarker profiling project is expected to enable a better understanding of how lifestyle, environment, and genetics combine to cause diseases.
The partners will make a test for monitoring Tysabri available to clinicians and clinical trial partners through ResearchDx's reference laboratory.
HP said it will coordinate with the CDC to first evaluate inkjet printing technology in regional labs and later explore a larger rollout in labs nationwide.
The partners aim to optimize DNA nanoball technology, accelerate the use of CTC technology, and work on a diagnostic tool for use at the point of care.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
The partners will work together to assess the use of rapid diagnostic tests in decentralized primary healthcare facilities in Malaysia.
By leveraging HealthShare's Informatic Exchange solution, Rhodes Group will create a longitudinal, standardized data repository across TriCore's laboratories.